MCK Stock Analysis — McKesson
Sector: Healthcare Distribution
AI Verdict
McKesson trades at a fair price for its steady growth and scale-driven moat, but you’re not getting a bargain unless earnings growth surprises to the upside.
Competitive Moat
McKesson operates one of the largest pharmaceutical distribution networks in North America, giving it scale advantages and entrenched relationships with hospitals and pharmacies. Its logistics infrastructure and regulatory expertise create high switching costs for customers and suppliers.
Summary
McKesson's scale in drug distribution makes it a critical middleman in the U.S. healthcare supply chain.
Where It Stands
McKesson is up 5.32% over the past year, trades at 18.5x next year's earnings (below the healthcare sector median of 22x), and its RSI of 37.9 signals shares are cooling toward oversold territory.
Key Metrics
- RSI: 37.9 — Near Oversold
- Trailing P/E: 19.6x
- Forward P/E: 18.5x
- PEG Ratio: 2.45
- Earnings Growth: +0.1%
- Revenue Growth: +0.1%
- Market Cap: $90.4B
- Dividend Yield: 0.00%
- 1-Year Return: 5.32%
- 5-Year Return: 2.881169266
- 52-Week High: $999.00
- 52-Week Low: $637.00
Analyst Consensus
20 Buy · 3 Hold · 0 Sell (23 analysts)
Bull Case
You’re paying 18.5x forward earnings for 6.4% expected EPS growth, which is a fair multiple for a defensive business with a $90.4B market cap and a 12.4% revenue growth print last year.
Bear Case
With a trailing PEG of 2.45, you’re paying a premium the earnings growth doesn’t fully support, and if the P/E reverts to the sector median of 22x, upside is limited to about 19% even if growth delivers.
Catalyst to Watch
Watch for margin expansion or new distribution contracts in quarterly results, as these could justify the current premium.